Clinical Therapeutic Efficacy of Montelukast on Cough Variant Asthma

Objective To evaluate the clinical therapeutic effect of montelukast on cough variant asthma.Methods After diagnostic therapy,86 children with cough variant asthma were randomly divided into therapy group (treated with oral montelukast,n=46) and control group (treated with inhaled fluticasone,n=40).Cough relaxation was observed during 6 months treatment.All patients were followed up 6 months after therapy to observe the relapse,evaluate the treatment efficiency,and count the days that patients had symptoms before treatment.The relapse rate after 6 months treatment was followed up.Results There were 40 effective patients and 6 ineffective patients (4 patients’ cough relaxation was observed after inhaling fluticasone) in therapy group,with the effective rate of 86.9%.There were 35 effective patients and 5 ineffective patients (cough relaxation was observed after receiving oral montelukast) in control group,with the effective rate of 87.5%.All patients were followed up 6 months after therapy.There were 4 patients of therapy group and 4 patients of control group recurred.No statistically significant difference was found in effective rate and relapse rate between the two groups (P0.05).The days that patients had symptoms before treatment in effective patients were significantly less than those in ineffective patients (P0.05).Conclusions The therapeutic effects of the two groups are similar,but it is more convenient to use montelukast.The therapeutic efficacy is correlated with the duration of the disease.Some patients need combined drugs,perhaps not only related with leukotriene,but also with many factors.